Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiprogrel in Acute Minor Ischaemic Stroke or High-risk TIA
NCT06601127Phase 2Recruiting
- Sponsor
- Tianjin Institute of Pharmaceutical Research
- Start
- Feb 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of taipugrel in ischemic stroke and Transient Ischemic Attack (TIA), sponsored by Tianjin Institute of Pharmaceutical Research. Primary endpoint: Percent of participants with ischemic stroke at 90 days. Started Feb 2025; status: recruiting.
02
Drugs
taipugrel
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06601127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06601127.